|
|
Article: Reports outline epilepsy therapy study results from Cardiff University.
- Article from:
- Biotech Week
- Article date:
- November 11, 2009
CopyrightCOPYRIGHT 2009 NewsRX. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Investigators publish new data in the report 'Visual field loss in patients with refractory partial epilepsy treated with vigabatrin: final results from an open-label, observational, multicentre study.' "Use of the antiepileptic drug vigabatrin is associated with an elevated risk of visual field loss. To determine the frequency of, and risk factors for, vigabatrin-attributed visual field loss (VAVFL) in the setting of a large-scale, multinational, prospective, observational study," scientists writing in the journal CNS Drugs report (see also Epilepsy Therapy).
"A comparative, open-label, parallel-group, multicentre study. Hospital outpatient clinics at 46 centres ...